BindRen

RSS
Withdrawn

This medicine's authorisation has been withdrawn

colestilan
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

The marketing authorisation for BindRen has been withdrawn at the request of the marketing authorisation holder.

български (BG) (622.19 KB - PDF)

View

español (ES) (541.57 KB - PDF)

View

čeština (CS) (603.24 KB - PDF)

View

dansk (DA) (560.1 KB - PDF)

View

Deutsch (DE) (562.92 KB - PDF)

View

eesti keel (ET) (539.24 KB - PDF)

View

ελληνικά (EL) (650.64 KB - PDF)

View

français (FR) (565.42 KB - PDF)

View

italiano (IT) (540.75 KB - PDF)

View

latviešu valoda (LV) (602.51 KB - PDF)

View

lietuvių kalba (LT) (564.62 KB - PDF)

View

magyar (HU) (599.75 KB - PDF)

View

Malti (MT) (609.45 KB - PDF)

View

Nederlands (NL) (538.37 KB - PDF)

View

polski (PL) (625.17 KB - PDF)

View

português (PT) (539.56 KB - PDF)

View

română (RO) (563.82 KB - PDF)

View

slovenčina (SK) (604.46 KB - PDF)

View

slovenščina (SL) (618.8 KB - PDF)

View

Suomi (FI) (540.67 KB - PDF)

View

svenska (SV) (539.51 KB - PDF)

View

Product information

български (BG) (2.56 MB - PDF)

View

español (ES) (1.17 MB - PDF)

View

čeština (CS) (1.88 MB - PDF)

View

dansk (DA) (1.19 MB - PDF)

View

Deutsch (DE) (1.19 MB - PDF)

View

eesti keel (ET) (1.16 MB - PDF)

View

ελληνικά (EL) (2.43 MB - PDF)

View

français (FR) (1.22 MB - PDF)

View

hrvatski (HR) (1.3 MB - PDF)

View

íslenska (IS) (1.18 MB - PDF)

View

italiano (IT) (1.18 MB - PDF)

View

latviešu valoda (LV) (1.96 MB - PDF)

View

lietuvių kalba (LT) (1.3 MB - PDF)

View

magyar (HU) (1.98 MB - PDF)

View

Malti (MT) (2.07 MB - PDF)

View

Nederlands (NL) (1.19 MB - PDF)

View

norsk (NO) (1.18 MB - PDF)

View

polski (PL) (2 MB - PDF)

View

português (PT) (1.18 MB - PDF)

View

română (RO) (1.35 MB - PDF)

View

slovenčina (SK) (2.04 MB - PDF)

View

slovenščina (SL) (1.93 MB - PDF)

View

Suomi (FI) (1.19 MB - PDF)

View

svenska (SV) (1.16 MB - PDF)

View
Latest procedure affecting product information: IAIN/0004
26/03/2015
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Product details

Name of medicine
BindRen
Active substance
colestilan
International non-proprietary name (INN) or common name
colestilan
Therapeutic area (MeSH)
Hyperphosphatemia
Anatomical therapeutic chemical (ATC) code
V03AE

Therapeutic indication

Treatment of hyperphosphataemia in adult patients with chronic kidney disease stage 5 receiving haemodialysis or peritoneal dialysis.

Authorisation details

EMA product number
EMEA/H/C/002377
Marketing authorisation holder
Mitsubishi Pharma Europe Ltd

Dashwood House
69 Old Broad Street
London EC2M 1QS
United Kingdom

Marketing authorisation issued
21/01/2013
Revision
2

Assessment history

This page was last updated on

Share this page